Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemdaneprocel in Parkinson's Disease
NCT06944522Phase 3Recruiting
- Sponsor
- BlueRock Therapeutics
- Start
- Jun 2025
- Primary completion
- Oct 2028
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of bemdaneprocel in Parkinson's disease (PD) (2 arms), sponsored by BlueRock Therapeutics. Primary endpoint: Change from baseline in PD diary measure of ON-time without troublesome dyskinesia at 78 weeks. Started Jun 2025; status: recruiting.
02
Drugs
bemdaneprocel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06944522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06944522.